Join our daily newsletter At The Bell to receive exclusive market insights
- Immuron (IMC) will deprioritise its SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates
- Immuron entered the new financial year with a newly appointed CEO at its helm, who has been working to complete an assessment of its entire product portfolio
- Following research, the company has determined that the rapid evolution of COVID and changing treatment landscape presents significant challenges to conduct a clinical trial of COVID-19 with IMM-124E
- As such, the company has been pursuing the antiviral activities of IMM-124E
- Immuron is steady, trading at 9.4 cents at 1:15 pm AEST
Immuron (IMC) has deprioritised SARS-COV-2 research to focus on the clinical development of its therapeutic drug candidates.
Immuron entered the new financial year with a newly appointed CEO at its helm, who has been working to complete an assessment of the entire product portfolio, target markets and key growth drivers.
Following its research, the company said the rapid evolution of COVID and the changing treatment landscape present significant challenges to conduct a clinical trial for COVID-19 with IMM-124E.
As such, the company has been pursuing the antiviral activities of IMM-124E, working to establish a better understanding of the mechanism of action associated with the neutralising activity of the drug against COVID.
Immuron reported it has dedicated significant resources to interrogate the mechanism of SARS-CoV-2 protection, however, the mechanism of how IMM-124E provides protection against viral infection remains unclear.
Immuron was steady, trading at 9.4 cents at 1:15 pm AEST.
